Red Queen Therapeutics, named after the Red Queen hypothesis in evolutionary biology, has emerged with a technology platform and drug pipeline to combat viral threats. The startup, backed by a $55 million Series A commitment from Apple Tree Partners, focuses on developing antivirals using stapled peptides that block viral fusion to cells. This novel approach overcomes limitations of traditional peptide drugs, allowing for room temperature storage and different delivery methods. The company’s lead program targets Covid-19, with promising Phase 1 results showing safety and potential efficacy. Red Queen plans to advance its Covid-19 drug to a Phase 2 study and explore partnerships for future development.
Source link
Startup Red Queen Therapeutics Unveils $55M and Tech to Defeat Elusive Viral Pathogens
